Novo Nordisk A/S (NYSE: NVO) just dropped some encouraging news for parents of younger kids struggling with obesity. On Monday, the company shared results from its STEP Young Phase 3 trial, which tested once-weekly semaglutide (the active ingredient in Wegovy) in children aged 6 to under 12 with obesity.

The trial hit its primary endpoint, showing a significantly bigger drop in body mass index (BMI) at week 68 for kids on semaglutide compared to those on a placebo. That's a big deal because this age group has limited clinically evaluated or approved treatment options when diet and exercise aren't enough.

Here's the headline number: after 68 weeks, 40.4% of kids treated with semaglutide were no longer classified as having obesity. Their BMI fell to overweight or normal levels. In the placebo group, that number was a flat zero. None of the kids on placebo made it out of the obesity category.

It's worth noting that over 85% of the children in the study started with severe obesity, classified as class II or class III. So these aren't borderline cases. Both groups also got lifestyle counseling, including a reduced-calorie diet and more physical activity, so the drug was tested on top of standard interventions.

The safety profile in this trial looked consistent with what we've seen in earlier adult and pediatric studies of semaglutide and liraglutide. No new safety issues popped up, and researchers didn't see any concerns about growth or pubertal development in these young patients. That's a key worry when you're talking about giving a powerful metabolic drug to kids whose bodies are still developing.

Obesity in children is a growing problem, and it's not just about weight. It can lead to serious health issues like type 2 diabetes, high blood pressure, and even psychological effects. Having a drug that actually works for younger kids could change how doctors approach treatment.

Investors seemed to take the news in stride, with Novo Nordisk shares down 1.85% at $45.73 in premarket trading on Tuesday. That might reflect broader market moves or the fact that the stock has already run up on obesity drug optimism.

Novo Nordisk is clearly betting big on expanding its obesity franchise beyond adults. Wegovy has been a blockbuster, and if regulators approve it for younger children, that opens up a whole new patient population. The company will likely submit these data to regulatory agencies soon, and it'll be interesting to see how the FDA and others respond.

For now, the results are promising, but they're just one trial. The real test will be whether the benefits hold up in the long run and whether the safety profile stays clean as kids grow into adolescence and beyond. But for families dealing with childhood obesity, this could be a glimmer of hope.